Urology News and Research

Latest Urology News and Research

Men above age 75 with high-risk prostate cancer often under-treated

Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.

22 Dec 2010

AHA recognizes UC Irvine Medical Center's commitment to high-quality cardiac care

The American Heart Association has recognized UC Irvine Healthcare's commitment to the highest standards of care for heart failure patients.

17 Dec 2010

New study suggests PSA test effective for men with prostate cancer

The PSA screening test for prostate cancer is not perfect. It can indicate cancer when none is present and miss life-threatening tumors. But a new study suggests the test is more reliable in men taking dutasteride (Avodart®), a drug widely prescribed to shrink an enlarged prostate gland.

17 Dec 2010

High-dose rate brachytherapy procedure to treat prostate cancer

Beaumont Hospital radiation oncologists have launched a research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation.

17 Dec 2010

UT Southwestern and Rabin Medical Center enter innovative 5-year affiliation agreement

UT Southwestern Medical Center and Rabin Medical Center, Israel, two of the world's top academic medical centers, announced today that they have entered into an innovative affiliation agreement for the next five years.

16 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.

15 Dec 2010

Yorkshire Cancer Research to grant over GBP1.26 million for research at universities of Leeds and Sheffield

Yorkshire Cancer Research (YCR) is set to give more than GBP1.26 million of funding to researchers at the universities of Leeds and Sheffield next year.

15 Dec 2010

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg.

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

NinePoint enters IP licensing agreement with Massachusetts General Hospital

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, NinePoint has certain exclusive rights in multiple fields to 188 patents and patent applications owned by MGH.

13 Dec 2010

Scientists create functioning human intestinal tissue from pluripotent stem cells

For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells.

13 Dec 2010

Simple molecular sensor color test to determine safe fluoride levels

Used in the proper amounts, it can make teeth stronger and aid in the treatment of osteoporosis. When excessive amounts are consumed, however, it can be a killer - a carcinogen that causes bone, lung and bladder cancers. The "it" is fluoride, a common additive in most American communities' drinking water and an ingredient in the vast majority of commercially produced adult toothpastes.

10 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Roughly one in three Medicare beneficiaries diagnosed with prostate cancer today gets a sophisticated form of radiation therapy called IMRT. …The story behind the sharp rise in the use of IMRT — which stands for intensity-modulated radiation therapy — is about more than just the rapid adoption of a new medical technology.

9 Dec 2010

Exergen's TemporalScanner demonstrates accuracy in temperature assessment for surgical patients

Temperatures taken orally or by temporal artery thermometry "are an accurate means of temperature assessment for adult patients undergoing colorectal or gynecology surgery," according to analysis published by the Journal of PeriAnesthesia Nursing. Accurate temperature readings are necessary to determine when to intervene for patients at all stages of their hospitalizations but especially during and immediately after surgical procedures to avoid post-operative complications.

9 Dec 2010

Researchers develop imaging technology that can accurately identify prostate cancer

Prostate cancer is the most common type of cancer among men, but its diagnosis has up to now been inaccurate and unpleasant. Researchers at Eindhoven University of Technology in the Netherlands, in cooperation with AMC Amsterdam, have developed an imaging technology that can accurately identify tumors.

8 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Watson, Natco confirm development agreement for generic Revlimid

Watson Pharmaceuticals, Inc. and Natco Pharma Limited today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10, 15 and 25 mg product. Natco's lenalidomide tablets are generic versions of Celgene's Revlimid ® Tablets.

7 Dec 2010

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

Columbia Laboratories, Inc. and Watson Pharmaceuticals, Inc. today announced positive top-line results from the PREGNANT Study, a large, global Phase III clinical trial evaluating PROCHIEVE® 8% vaginal progesterone gel to reduce the risk of preterm birth in women with a short cervical length as measured by transvaginal ultrasound at mid-pregnancy.

7 Dec 2010

Urology News and Research

Latest Urology News and Research

Men above age 75 with high-risk prostate cancer often under-treated

AHA recognizes UC Irvine Medical Center's commitment to high-quality cardiac care

New study suggests PSA test effective for men with prostate cancer

High-dose rate brachytherapy procedure to treat prostate cancer

UT Southwestern and Rabin Medical Center enter innovative 5-year affiliation agreement

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

Yorkshire Cancer Research to grant over GBP1.26 million for research at universities of Leeds and Sheffield

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

NinePoint enters IP licensing agreement with Massachusetts General Hospital

Scientists create functioning human intestinal tissue from pluripotent stem cells

Simple molecular sensor color test to determine safe fluoride levels

Expert discusses androgen deprivation therapy for prostate cancer

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Exergen's TemporalScanner demonstrates accuracy in temperature assessment for surgical patients

Researchers develop imaging technology that can accurately identify prostate cancer

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Watson, Natco confirm development agreement for generic Revlimid

Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Urology News and Research

Latest Urology News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in